Category Archives: Biotechnology

Where Does Gossamer Bio Inc (GOSS) Stock Fall in the Biotechnology Field After It Is Lower By -4.73% This Week?  InvestorsObserver

See more here:
Where Does Gossamer Bio Inc (GOSS) Stock Fall in the Biotechnology Field After It Is Lower By -4.73% This Week? - InvestorsObserver

Where Does Pliant Therapeutics Inc (PLRX) Stock Fall in the Biotechnology Field After It Is Lower By -5.27% This Week?  InvestorsObserver

See original here:
Where Does Pliant Therapeutics Inc (PLRX) Stock Fall in the Biotechnology Field After It Is Lower By -5.27% This Week? - InvestorsObserver

Where Does ADMA Biologics Inc (ADMA) Stock Fall in the Biotechnology Field After It Is Lower By -4.23% This Week?  InvestorsObserver

See the rest here:
Where Does ADMA Biologics Inc (ADMA) Stock Fall in the Biotechnology Field After It Is Lower By -4.23% This Week? - InvestorsObserver

Is Harmony Biosciences Holdings Inc (HRMY) Stock at the Top of the Biotechnology Industry?  InvestorsObserver

View post:
Is Harmony Biosciences Holdings Inc (HRMY) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

CLICK HERE FOR PROGRAM NEWS, EVENTS, AND ANNOUNCEMENTS!

The Biotechnology MA program trains students in modern aspects of molecular biology with a particular emphasis on approaches used in the biotechnology and pharmaceutical industries. The program provides students with an advanced scientific education and prepares them scientifically for diverse careers in the Biotechnology and Pharmaceutical industries. These careers include:

The program is intended for students who would like a career in biotechnology without making the 5-7 year commitment to attain a Ph.D. The biotechnology and pharmaceutical industries are among the largest in the U.S. and there is a great demand for professionals with biotechnology expertise.

Thirty (30) points of coursework plus a Master's thesis are required for the MA in Biotechnology. The thesis includes a review of a topic in biotechnology chosen with the help of a program advisor. An intensive laboratory course in Biotechnology is required to give students hands on experience in biotechnology methods. Elective courses (five or more) are selected according to the students specific interests. The program can be completed by full-time students in 1 year including the summer semester or at a reduced pace by part-time students.

See the rest here:
M.A. Biotechnology Program - Columbia University

Current Opinion in Biotechnology (COBIOT) publishes authoritative, comprehensive, and systematic reviews. COBIOT helps specialists keep up to date with a clear and readable synthesis on current advances biotechnology. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.

Current Opinion in Biotechnology is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Biotechnology (CRBIOT). CO+RE journals leverage the Current Opinion legacy?of editorial excellence, high-impact, and global reach?to ensure they are a widely read resource that is integral to scientists? workflow.

Current Opinion in Biotechnology is divided into themed sections, each of which is reviewed once a year. Themes include analytical biotechnology; plant biotechnology; food biotechnology; energy biotechnology; environmental biotechnology; systems biology; nanobiotechnology; tissue, cell and pathway engineering; chemical biotechnology; and pharmaceutical biotechnology.

The journal builds on Elsevier?s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.

Selection of topics to be reviewed Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.

ReviewsAuthors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.

Review articles in Current Opinion in Biotechnology are by invitation only.

Editorial OverviewSection Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.

Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

For more information, please refer to: https://www.elsevier.com/conflictsofinterest

See the original post:
Current Opinion in Biotechnology | Journal - ScienceDirect

Public UK Research Council on Life Sciences

Region served

Chair

Main organ

Parent organization

Budget

Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, is a non-departmental public body (NDPB), and is the largest UK public funder of non-medical bioscience. It predominantly funds scientific research institutes and university research departments in the UK.

Receiving its funding through the science budget of the Department for Business, Energy and Industrial Strategy (BEIS), BBSRC's mission is to "promote and support, by any means, high-quality basic, strategic and applied research and related postgraduate training relating to the understanding and exploitation of biological systems".[1]

BBSRC's head office is at Polaris House [2] in Swindon - the same building as the other councils of UK Research and Innovation, AHRC EPSRC, ESRC, Innovate UK, MRC, NERC, Research England and STFC, as well as the UKSA. Funded by Government, BBSRC invested over 498 million in bioscience in 201718. BBSRC also manages the joint Research Councils' Office in Brussels the UK Research Office (UKRO).

BBSRC was created in 1994, merging the former Agricultural and Food Research Council (AFRC) and taking over the biological science activities of the former Science and Engineering Research Council (SERC).[3]

Chairs

Chief executives

Executive chairs

BBSRC is managed by the BBSRC Council consisting of a chair (from 2015, Professor Sir Gordon Duff), an executive chair (Professor Melanie Welham) and from ten to eighteen representatives from UK universities, government and industry. The council approves policies, strategy, budgets and major funding.

A research panel provides expert advice which BBSRC Council draws upon in making decisions. The purpose of the research panel is to advise on:

In addition to the council and the research panel, BBSRC has a series of other internal bodies for specific purposes.

The council strategically funds eight research institutes in the UK, and a number of centres (BBSRC: Institutes and centres).

They have strong links with business, industry and the wider community, and support policy development.[citation needed]

The institutes' research underpins key sectors of the UK economy such as agriculture, bioenergy, biotechnology, food and drink and pharmaceuticals. In addition, the institutes maintain unique research facilities of national importance.

Other research institutes have merged with each other or with local universities. Previous BBSRC (or AFRC) sponsored institutes include:

Here is the original post:
Biotechnology and Biological Sciences Research Council

Should Biotechnology Stock LogicBio Therapeutics Inc (LOGC) Be in Your Portfolio Tuesday?  InvestorsObserver

Go here to read the rest:
Should Biotechnology Stock LogicBio Therapeutics Inc (LOGC) Be in Your Portfolio Tuesday? - InvestorsObserver

PDS BIOTECHNOLOGY CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)  Marketscreener.com

Read more:
PDS BIOTECHNOLOGY CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - Marketscreener.com

Is Brainstorm Cell Therapeutics Inc (BCLI) Stock at the Top of the Biotechnology Industry?  InvestorsObserver

More here:
Is Brainstorm Cell Therapeutics Inc (BCLI) Stock at the Top of the Biotechnology Industry? - InvestorsObserver